Mallinckrodt, a leading global specialty pharmaceuticals business, has entered into an agreement with US-based, Amneal Pharmaceuticals LLC to distribute to addiction treatment centres its Buprenorphine HCl and Naloxone HCl Dihydrate Sublingual Tablets (CIII), a generic version of Suboxone, manufactured in Amneal’s Hauppauge, New York, facility. The product is a prescription medication indicated for the maintenance treatment of opioid dependence. The contract covers a period of three years, with an option to extend.
Mallinckrodt is a major supplier of generic opioid dependence products to US addiction treatment centres. The Company is leveraging its long-established supply chain expertise to extend the number of products it distributes to these centres.
“The core competencies we have built during the course of our 145-year history, particularly our extensive distribution network and expertise in handling controlled substances, make us an ideal partner for Amneal,” said Walt Kaczmarek, vice president and general manager, Specialty Generics, Mallinckrodt. “This agreement demonstrates our continued focus to unlock our potential and drive growth based on what we do well, within our generic specialty pharmaceuticals business.”
This collaboration, the first between Mallinckrodt and Amneal, covers both strengths of Buprenorphine HCl and Naloxone HCl Dihydrate Sublingual Tablets (CIII) available on the market, the 8 mg/2 mg dosage strength and the 2 mg/0.5 mg dosage strength.
Mallinckrodt develops, manufactures, markets, and distributes specialty pharmaceutical products and medical imaging agents.